Hubbry Logo
BisphosphonateBisphosphonateMain
Open search
Bisphosphonate
Community hub
Bisphosphonate
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Bisphosphonate
Bisphosphonate
Bisphosphonate
View on Wikipedia
from Wikipedia
The general chemical structure of bisphosphonate. The R-groups determine the chemical properties of the drug, and distinguishes individual types of bisphosphonates. This chemical structure affords a high affinity for calcium hydroxyapatite, allowing for rapid and specific skeletal targeting.

Bisphosphonates are a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases. They are the most commonly prescribed to treat osteoporosis.[1]

Evidence shows that they reduce the risk of fracture in post-menopausal women with osteoporosis.[2][3][4][5][6]

Bone tissue undergoes constant remodeling and is kept in balance (homeostasis) by osteoblasts creating bone and osteoclasts destroying bone. Bisphosphonates inhibit the digestion of bone by encouraging osteoclasts to undergo apoptosis, or cell death, thereby slowing bone loss.[7]

The uses of bisphosphonates include the prevention and treatment of osteoporosis, Paget's disease of bone, bone metastasis (with or without hypercalcemia), multiple myeloma, primary hyperparathyroidism, osteogenesis imperfecta, fibrous dysplasia, and other conditions that exhibit bone fragility.

Chemical structure and mechanistic aspects

[edit]

The term bisphosphonate refers to the presence two phosphonate (PO2(OH)−) groups. They are also called diphosphonates (bis- or di- + phosphonate). The PO2(OH)− groups readily lose an additional proton, giving (PO2−3 groups, which have a particularly high affinity for metal ions.


They are structurally close analogues of pyrophosphate (abbreviated PPi).[8]. Like pyrophosphate, bisphosphonates inhibit the growth and dissolution of bone. Unlike pyrophosphate, bis(phosphonates) are very stable in aqueous solution. They resist breakdown by hydrolysis because the P-C-P or P-N-P linkages are more robust than P-O-P linkages. Bis(phosponate)s are proposed to interfere with osteoclasts, which cause bone resorption.

Medical uses

[edit]

Bisphosphonates are used to treat osteoporosis, osteitis deformans (Paget's disease of the bone), bone metastasis (with or without hypercalcemia), multiple myeloma, and other conditions involving fragile, breakable bone.

In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are alendronate and risedronate. If these are ineffective or if the person develops digestive tract problems, intravenous pamidronate may be used. Strontium ranelate or teriparatide are used for refractory disease. The use of strontium ranelate is restricted because of increased risk of venous thromboembolism, pulmonary embolism and serious cardiovascular disorders, including myocardial infarction.[9] In postmenopausal women, the selective estrogen receptor modulator raloxifene is occasionally administered instead of bisphosphonates. Bisphosphonates are beneficial in reducing the risk of vertebral fracture in steroid induced osteoporosis.[10]

Post-menopausal osteoporosis

[edit]

Bisphosphonates are recommended as a first line treatments for post-menopausal osteoporosis.[5][11][12][13]

Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment.[2] The bisphosphonate alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%; zoledronate reduces the risk of hip fractures by 38% and of vertebral fractures by 62%.[3][4] Risedronate has also been shown to reduce the risk of hip fractures.[5][6]

After five years of medications by mouth or three years of intravenous medication among those at low risk, bisphosphonate treatment can be stopped.[14] In those at higher risk, ten years of medication by mouth or six years of intravenous treatment may be used.[14]

Cancer

[edit]

Bisphosphonates reduce the risk of fracture and bone pain[15] in people with breast,[16] lung,[17] and other metastatic cancers as well as in people with multiple myeloma.[18] In breast cancer, there is mixed evidence regarding whether bisphosphonates improve survival.[16][19][20][21] A 2017 Cochrane review found that for people with early breast cancer, bisphosphonate treatment may reduce the risk of the cancer spreading to the person's bone, however, for people who had advanced breast cancer bisphosphonate treatment did not appear to reduce the risk of the cancer spreading to the bone.[16] Side effects associated with bisphosphonate treatment for people with breast cancer are mild and rare.[16]

Bisphosphonates can also reduce mortality in those with multiple myeloma and prostate cancer.[21]

Other

[edit]

Evidence suggests that the use of bisphosphonates would be useful in the treatment of complex regional pain syndrome, a neuro-immune problem with high MPQ scores, low treatment efficacy and symptoms which can include regional osteoporosis. In 2009, bisphosphonates were "among the only class of medications that have survived placebo-controlled studies showing statistically significant improvement (in CRPS) with therapy."[22]

There is observational evidence and molecular explanation for some bisphosphonates offering a level of protection against COVID-19.[23][24]

Bisphosphonates have been used to reduce fracture rates in children with the disease osteogenesis imperfecta[25] and to treat otosclerosis[26] by minimizing bone loss.

Other bisphosphonates, including medronate (R1=H, R2=H) and oxidronate (R1=H, R2=OH), are mixed with radioactive technetium and injected, as a way to image bone and detect bone disease.

Adverse effects

[edit]

Common

[edit]

Oral bisphosphonates can cause upset stomach and inflammation and erosions of the esophagus, which is the main problem of oral N-containing[further explanation needed] preparations, that is, ones containing "normal" unbranched chains. This can be prevented by remaining seated upright for 30 to 60 minutes after taking the medication. Intravenous bisphosphonates can give fever and flu-like symptoms after the first infusion, which is thought to occur because of their potential to activate human γδ T cells.

Bisphosphonates, when administered intravenously for the treatment of cancer, have been associated with osteonecrosis of the jaw (ONJ), with the mandible twice as frequently affected as the maxilla and most cases occurring following high-dose intravenous administration used for some cancer patients. Phossy jaw has been described since Victorian times. Some 60% of cases are preceded by a dental surgical procedure (that involves the bone), and it has been suggested that bisphosphonate treatment should be postponed until after any dental work to eliminate potential sites of infection (the use of antibiotics may otherwise be indicated before any surgery).[27]

Several cases of severe bone, joint, or musculoskeletal pain have been reported, prompting labeling changes.[28]

Some studies have identified bisphosphonate use as a risk factor for atrial fibrillation (AF), though a meta-analysis of them found conflicting reports. As of 2008, the US Food and Drug Administration did not recommend any alteration in the prescribing of bisphosphonates based on AF concerns.[29] More recent meta-analyses have found strong correlations between bisphosphonate use and development of AF, especially when administered intravenously,[30] but that a significantly increased risk of AF that required hospitalization did not have an attendant increased risk of stroke or cardiovascular mortality.[31]

Long-term risks

[edit]

In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the femur (thigh bone) in the shaft (diaphysis or sub-trochanteric region) of the bone, rather than at the femoral neck, which is the most common site of fracture. However, these fractures are rare (12 in 14,195 women) compared to the common hip fractures (272 in 14,195 women), and the overall reduction in hip fractures caused by bisphosphonate is more than the increase in unusual shaft fractures.[32][obsolete source] There are concerns that long-term bisphosphonate use can result in over-suppression of bone turnover. It is hypothesized that micro-cracks in the bone are unable to heal and eventually unite and propagate, resulting in atypical fractures. Such fractures tend to heal poorly and often require some form of bone stimulation, for example, bone grafting as a secondary procedure. This complication is uncommon, and the benefit of overall fracture reduction still holds.[32][33][non-primary source needed] In cases where there is concern of such fractures occurring, teriparatide is potentially a good alternative because it does not cause as much damage as a bisphosphonate does by suppressing bone turnover.[34]

Three meta-analyses have evaluated whether bisphosphonate use is associated with an increased risk of esophageal cancer. Two studies concluded that there was no evidence of increased risk.[35][36][37]

Chemistry and classes

[edit]

All bisphosphonate drugs share a common phosphorus-carbon-phosphorus "backbone":

The two PO
3 (phosphonate) groups covalently linked to carbon determine both the name "bisphosphonate" and the function of the drugs. Bis refers to the fact that there are two such groups in the molecule.

The long side-chain (R2 in the diagram) determines the chemical properties, the mode of action, and the strength of bisphosphonate drugs. The short side-chain (R1), often called the 'hook', mainly influences chemical properties and pharmacokinetics.

See nitrogenous and non-nitrogenous sections in Mechanism of action below.

Pharmacokinetics

[edit]

Of the bisphosphonate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidneys. The remainder has a very high affinity for bone tissue, and is rapidly adsorbed onto the bone surface. Once bisphosphonates are in bone, they have a very long elimination half-life that can exceed ten years.[38]

Mechanism of action

[edit]

Bisphosphonates are structurally similar to pyrophosphate, but with a central carbon that can have up to two substituents (R1 and R2) instead of an oxygen atom. Because a bisphosphonate group mimics the structure of pyrophosphate, it can inhibit activation of enzymes that utilize pyrophosphate.

The specificity of bisphosphonate-based drugs comes from the two phosphonate groups (and possibly a hydroxyl at R1) that work together to coordinate calcium ions. Bisphosphonate molecules preferentially bind to calcium ions. The largest store of calcium in the human body is in bones, so bisphosphonates accumulate to a high concentration only in bones.

Bisphosphonates, when attached to bone tissue, are released by osteoclasts, the bone cells that break down bone tissue. Bisphosphonate molecules then attach to and enter osteoclasts where they disrupt intracellular enzymatic functions needed for bone resorption.[39]

There are two classes of bisphosphonate compounds: non-nitrogenous (no nitrogen in R2) and nitrogenous (R2 contains nitrogen). The two types of bisphosphonates work differently in inhibiting osteoclasts.

Class Name R1 R2 Relative potency
(vs Etidronate=1)
Non-nitrogenous
 Etidronate (Didronel) OH CH3 1
Clodronate (Bonefos, Loron) Cl Cl 10
Tiludronate (Skelid) H p-Chlorophenylthio 10
Nitrogenous
 Pamidronate (APD, Aredia) OH [CH2]2NH2 100
Neridronate (Nerixia[a]) OH [CH2]5NH2 100
Olpadronate OH [CH2]2N(CH3)2 500
Alendronate (Fosamax) OH [CH2]3NH2 500
Ibandronate (Boniva - US, Bonviva - Asia) OH [CH2]2N(CH3)[CH2]4CH3 1000
Risedronate (Actonel) OH 3-Pyridylmethyl 2000
Zoledronate (Zometa, Aclasta) OH 1H-imidazol-1-ylmethyl 10000

Non-nitrogenous

[edit]

The non-nitrogenous bisphosphonates (diphosphonates) are metabolised in the cell to compounds that replace the terminal pyrophosphate moiety of ATP, forming a non-functional molecule that competes with adenosine triphosphate (ATP) in the cellular energy metabolism. The osteoclast initiates apoptosis and dies, leading to an overall decrease in the breakdown of bone. This type of bisphosphonate has overall more negative effects than the nitrogen containing group, and is prescribed far less often.[40]

Nitrogenous

[edit]

Nitrogenous bisphosphonates act on bone metabolism by binding and blocking the enzyme farnesyl diphosphate synthase (FPPS) in the HMG-CoA reductase pathway (also known as the mevalonate pathway).[41]

Bisphosphonates that contain isoprene chains at the R1 or R2 position can impart specificity for inhibition of GGPS1.[42]

HMG-CoA reductase pathway

Disruption of the HMG CoA-reductase pathway at the level of FPPS prevents the formation of two metabolites (farnesol and geranylgeraniol) that are essential for connecting some small proteins to the cell membrane. This phenomenon is known as prenylation, and is important for proper sub-cellular protein trafficking (see "lipid-anchored protein" for the principles of this phenomenon).[43]

While inhibition of protein prenylation may affect many proteins found in an osteoclast, disruption to the lipid modification of Ras, Rho, Rac proteins has been speculated to underlie the effects of bisphosphonates. These proteins can affect osteoclastogenesis, cell survival, and cytoskeletal dynamics. In particular, the cytoskeleton is vital for maintaining the "ruffled border" that is required for contact between a resorbing osteoclast and a bone surface.

Statins are another class of drugs that inhibit the HMG-CoA reductase pathway. Unlike bisphosphonates, statins do not bind to bone surfaces with high affinity, and thus are not specific for bone. Nevertheless, some studies have reported a decreased rate of fracture (an indicator of osteoporosis) and/or an increased bone mineral density in statin users. The overall efficacy of statins in the treatment of osteoporosis remains controversial.[44]

History

[edit]
Main article: Discovery and development of bisphosphonates

Bisphosphonates were developed in the 19th century but were first investigated in the 1960s for use in disorders of bone metabolism. Their non-medical use was to soften water in irrigation systems used in orange groves. The initial rationale for their use in humans was their potential in preventing the dissolution of hydroxylapatite, the principal bone mineral, thus arresting bone loss. In the 1990s their actual mechanism of action was demonstrated with the initial launch of alendronate by Merck & Co.[45]

Notes

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Bisphosphonate

View on Grokipedia
from Grokipedia
Bisphosphonates are a class of synthetic drugs characterized by a phosphorus-carbon-phosphorus (P-C-P) backbone that mimics inorganic , primarily used to inhibit -mediated and treat conditions involving excessive loss, such as , , and metastases from cancer. First synthesized in the late as antiscaling agents for industrial use, bisphosphonates were recognized for their effects on in the , with clinical applications expanding in the 1990s following the development of more potent nitrogen-containing variants like alendronate and . They are classified into two main groups: non-nitrogen-containing bisphosphonates (e.g., etidronate, clodronate), which incorporate into (ATP) to form cytotoxic analogs that induce , and nitrogen-containing bisphosphonates (e.g., pamidronate, ibandronate, risedronate), which inhibit the enzyme farnesyl pyrophosphate synthase in the , disrupting function and survival. This selective action on occurs because bisphosphonates bind strongly to in areas of high turnover, achieving a prolonged skeletal of 1 to 10 years or more, while exhibiting poor oral (less than 1%) and rapid renal clearance of unbound drug. Clinically, bisphosphonates are indicated for postmenopausal , glucocorticoid-induced , male , hypercalcemia of , Paget's disease, and skeletal-related events in or solid tumors with bone metastases, with FDA-approved examples including alendronate (oral weekly), risedronate (oral weekly or monthly), ibandronate (oral monthly or intravenous quarterly), and (intravenous annually). They reduce fracture risk by increasing bone mineral density and suppressing bone turnover markers, with studies showing up to a 28% reduction in mortality in certain high-risk populations, such as those with recent hip fractures. Administration requires precautions: oral forms must be taken upright with water on an empty stomach, followed by a 30- to 60-minute upright posture to prevent esophageal irritation, while intravenous forms may cause acute-phase reactions like fever or flu-like symptoms in up to 30% of initial doses. Common adverse effects include gastrointestinal disturbances (e.g., dyspepsia, ) with oral bisphosphonates and (up to 18% incidence), while rare but serious risks encompass (incidence 1 in 10,000 to 100,000 patient-years, higher with intravenous use or dental procedures), atypical femoral fractures (3.2 to 50 per 100,000 person-years after prolonged therapy), and . Contraindications include , uncorrected , severe renal impairment ( <30–35 mL/min), esophageal abnormalities, and prior or atypical fractures. Long-term use prompts consideration of "drug holidays" after 3 to 5 years in low-risk patients to balance benefits against rare complications, with monitoring via bone density scans and turnover markers.

Chemistry

Molecular Structure

Bisphosphonates are synthetic analogues of the endogenous molecule pyrophosphate, featuring a characteristic P-C-P backbone in which the central oxygen atom of pyrophosphate is replaced by a carbon atom. This structural modification confers resistance to enzymatic hydrolysis by phosphatases, enabling the compounds to persist in biological environments. The general molecular formula of bisphosphonates is \ce(HO)2P(O)−C(R1)(R2)−P(O)(OH)2\ce{(HO)2P(O)-C(R1)(R2)-P(O)(OH)2}, where the two phosphonate groups are geminally linked to a central carbon atom, and the substituents R1 and R2 modulate the compound's potency and tissue specificity. For instance, a hydroxyl group at the R1 position significantly enhances affinity for bone mineral by facilitating tridentate binding to calcium ions. Structural variations among bisphosphonates primarily arise from modifications to the R1 and R2 side chains. Simple bisphosphonates, such as etidronate, feature basic alkyl or hydroxyl substituents, while more advanced variants incorporate heterocyclic rings (e.g., imidazole in zoledronate) or amino-containing side chains in nitrogen-bearing types (e.g., primary amine in pamidronate or secondary amine in risedronate), which influence their biochemical interactions. Due to their two highly polar phosphonate moieties, bisphosphonates exhibit high polarity and low lipophilicity, resulting in poor passive diffusion across cell membranes and reliance on fluid-phase endocytosis for cellular uptake. These properties also promote strong adsorption to hydroxyapatite crystals in bone mineral, with binding affinities varying based on side-chain composition but generally exceeding that for other tissues.

Classification

Bisphosphonates are broadly classified into two main chemical classes based on the presence or absence of nitrogen in the R2 side chain of their molecular structure: non-nitrogenous and nitrogenous. Non-nitrogenous bisphosphonates, such as etidronate, clodronate, and tiludronate, lack nitrogen and closely mimic the structure of pyrophosphate, exhibiting relatively low antiresorptive potency. In comparison, nitrogenous bisphosphonates, exemplified by alendronate, risedronate, zoledronate, and ibandronate, incorporate a nitrogen-containing side chain that dramatically enhances their potency, making them 100 to 10,000 times more effective at inhibiting bone resorption than non-nitrogenous counterparts. These classes further align with generational developments in bisphosphonate design, reflecting chronological advancements in potency and structural complexity since the 1970s. First-generation bisphosphonates are non-nitrogenous (e.g., etidronate, clodronate, tiludronate), introduced in the 1970s with basic antiresorptive activity. Second-generation agents are alkyl nitrogenous bisphosphonates (e.g., alendronate, pamidronate), developed in the 1980s and offering 10- to 100-fold greater potency than first-generation drugs. Third-generation bisphosphonates are cyclic or heterocyclic nitrogenous compounds (e.g., risedronate, zoledronate), emerging in the 1990s and 2000s, with up to 10,000-fold potency relative to first-generation ones. Nitrogenous bisphosphonates encompass distinct subtypes defined by the nitrogen-bearing side chain configuration. These include alkyl amine subtypes, such as alendronate (primary amine) and ibandronate (tertiary amine); and heterocyclic subtypes featuring ring structures like the pyridine ring in risedronate or the imidazole ring in zoledronate. Antiresorptive potency among bisphosphonates generally follows the ranking zoledronate > risedronate > ibandronate > alendronate > non-nitrogenous bisphosphonates (e.g., etidronate ≈ clodronate), with this order correlating to structural modifications that improve binding affinity and cellular inhibition. This classification builds on the shared P-C-P core backbone common to all bisphosphonates, which provides their fundamental bone-targeting properties.

Pharmacology

Mechanism of Action

Bisphosphonates primarily inhibit by targeting osteoclasts, the cells responsible for bone breakdown. These compounds exhibit a strong affinity for , the mineral component of , allowing them to bind selectively to exposed bone surfaces at sites of active remodeling. During the resorptive process, osteoclasts acidify the extracellular environment, solubilizing the bound bisphosphonates, which are then internalized by the osteoclasts via fluid-phase . This uptake disrupts normal osteoclast function, leading to morphological changes, loss of resorptive activity, and ultimately , without significantly affecting osteoblasts or bone formation. The varies between the two main classes of bisphosphonates. Non-nitrogenous bisphosphonates, such as clodronate and etidronate, are metabolically activated within to form cytotoxic analogues of (ATP), exemplified by AppCCl₂p from clodronate. These ATP analogues accumulate intracellularly and interfere with mitochondrial function by competitively inhibiting the ADP/ATP translocase, thereby disrupting cellular energy metabolism and inducing rapid osteoclast death. Nitrogenous bisphosphonates, including alendronate, risedronate, and zoledronate, are substantially more potent and operate through inhibition of synthase (FPPS), a crucial in the . By blocking FPPS, these agents prevent the production of isoprenoid precursors, particularly and , which are essential for the (geranylgeranylation) of small GTP-binding proteins such as Rho, Rac, and Cdc42. Impaired disrupts the trafficking and function of these , resulting in the retraction of the osteoclast's ruffled border—a specialized structure required for —cytoskeletal disorganization, and subsequent . Nitrogenous bisphosphonates achieve higher intracellular concentrations through efficient fluid-phase , enhancing their antiresorptive efficacy compared to non-nitrogenous counterparts. The inhibitory effects of bisphosphonates on osteoclasts are dose-dependent. At lower doses, they primarily suppress osteoclast recruitment, differentiation, and activation, reducing the overall number of functional resorbing cells. Higher doses induce direct in mature osteoclasts, amplifying the apoptotic response. This selective action on osteoclasts, sparing osteoblasts, helps maintain a balance that favors net preservation.

Pharmacokinetics

Bisphosphonates exhibit poor oral , typically ranging from less than 1% to 5%, primarily due to their high polarity and at physiological , which limits gastrointestinal absorption. This absorption occurs mainly in the , , and via paracellular or pathways, but it is significantly reduced by concomitant intake of food, beverages, or divalent cations such as calcium and magnesium, including those found in supplements, which form insoluble complexes with the drugs. To minimize this interaction, magnesium-rich supplements or medications should be taken at least 2 hours before or after the oral bisphosphonate dose. In contrast, intravenous administration, as with zoledronate, achieves 100% , bypassing gastrointestinal barriers. Following absorption or administration, bisphosphonates demonstrate rapid distribution to tissue, where 50% to 70% of the dose is taken up selectively by crystals, particularly at sites of high bone turnover such as trabecular . penetration is minimal, and is generally low, varying from 5% to less than 50% depending on the specific bisphosphonate, , and calcium levels. Once bound to , bisphosphonates exhibit an extended skeletal ranging from years to decades; for example, alendronate has a bone estimated at over 10 years. Bisphosphonates are not subject to systemic , as they remain chemically and are excreted largely unchanged. However, non-nitrogen-containing bisphosphonates, such as clodronate and etidronate, may undergo intracellular within osteoclasts to form cytotoxic ATP analogues. Elimination of bisphosphonates occurs primarily through renal of the unbound fraction, with 20% to 50% of the dose cleared via within 24 hours via glomerular . The serves as a long-term reservoir, releasing the drugs slowly during , which contributes to their prolonged terminal of 1 to 10 years or more across the class. There is no hepatic involved in their clearance. Special considerations apply in patients with renal impairment, where clearance is reduced and prolonged; dose adjustments or avoidance are recommended for clearance below 35 mL/min, as seen with alendronate, to prevent accumulation and potential .

Medical Uses

Bisphosphonates are established as first-line therapy for the prevention and treatment of , particularly in postmenopausal women, where they reduce fracture risk by inhibiting osteoclast-mediated . Approved agents for this indication include alendronate, risedronate, ibandronate, and , which increase density (BMD) by 5-8% at the lumbar spine and hip over 3 years of treatment. This BMD improvement helps restore the balance disrupted by accelerated following decline in postmenopausal women, without introducing hormonal effects. Clinical trials demonstrate substantial efficacy in fracture risk reduction, with bisphosphonates lowering vertebral fractures by 40-70% and fractures by 20-50%. For example, in the Fracture Intervention Trial (FIT), alendronate reduced fractures by 51% in postmenopausal women with existing vertebral fractures over 3 years. These reductions are consistent across agents, supporting their role in managing primary osteoporosis by targeting high-risk sites like the spine and . Treatment regimens vary by agent to improve adherence: alendronate is administered orally at 70 mg weekly, ibandronate at 150 mg orally monthly, risedronate at 35 mg orally weekly, and at 5 mg intravenously yearly. typically lasts 3-5 years, after which a may be considered for lower-risk patients to balance benefits and potential long-term risks, with monitoring of BMD and fracture risk. In specific populations, bisphosphonates show tailored efficacy; risedronate, along with alendronate, is effective for glucocorticoid-induced due to its demonstrated prevention of bone loss in this setting. Alendronate is effective in male , increasing BMD at the spine, , and total body while reducing vertebral risk.

Oncology

Bisphosphonates play a crucial role in by preventing skeletal-related events (SREs), such as pathologic fractures, , need for or to , and hypercalcemia, in patients with bone metastases from solid tumors including and cancers, as well as . Key agents include intravenous at 4 mg every 3-4 weeks and pamidronate at 90 mg every 3-4 weeks, both approved for use in and , with also indicated for other solid tumors with bone involvement. Clinical trials, such as those evaluating (Zometa), have demonstrated a 20-40% reduction in SRE risk; for instance, in patients, reduced SREs by 39% compared to (p=0.027), while in , it lowered the SRE rate from 49% to 38% (p=0.028). In postmenopausal women with early-stage , adjuvant bisphosphonate therapy (e.g., oral clodronate, ibandronate, or risedronate; intravenous ) for 2-5 years reduces the risk of distant recurrence by approximately 18% and breast cancer mortality by 9%, particularly in bone, based on meta-analyses of randomized trials. This benefit is most pronounced in postmenopausal patients and is recommended in guidelines for those at sufficient risk. In the treatment of hypercalcemia of malignancy, bisphosphonates rapidly normalize serum calcium levels by inhibiting osteoclast-mediated osteolysis, achieving response rates of 80-90%. has shown superior efficacy over pamidronate, with complete response rates by day 10 reaching 88.4% for 4 mg and 8 mg doses (p=0.002 and p=0.015, respectively), compared to 70.0% for pamidronate 90 mg. These agents are administered as a single intravenous infusion, providing rapid onset and durable normocalcemia in most cases. For , bisphosphonates serve as a standard adjunct to , delaying the progression of lesions and reducing SRE incidence. Intravenous pamidronate and , dosed every 3-4 weeks, have comparable efficacy in preventing SREs (47% vs. 51% incidence), with also decreasing the risk of vertebral fractures (p=0.01). Nitrogen-containing bisphosphonates like and pamidronate are preferred due to their higher potency in inhibiting compared to non-nitrogenous agents. Preclinical models suggest potential direct anti-tumor effects through inhibition of the , impairing Ras protein and membrane localization in cancer cells, though this is not their primary mechanism in clinical use.

Other Indications

Bisphosphonates are employed in the management of through high-dose, short-term regimens, such as a single intravenous dose of 5 mg zoledronate, which normalizes serum levels in approximately 89% of patients and promotes remodeling of abnormal bone structure. This approach achieves rapid and sustained biochemical remission, outperforming oral risedronate in comparative trials, with effects lasting up to several years in many cases. In , particularly in pediatric patients, cyclic intravenous pamidronate therapy enhances bone mineral and substantially reduces incidence. Seminal studies demonstrate that such treatment, administered in escalating doses over multiple cycles, increases vertebral bone by up to 42% after one year and decreases the annual rate from an average of 2.2 to 0.6 per patient. For the prevention of heterotopic following hip arthroplasty or , bisphosphonates like etidronate and pamidronate have shown prophylactic efficacy. Etidronate, given orally at 20 mg/kg daily for three months post-surgery, significantly lowers the incidence of clinically significant compared to controls, while pamidronate has been effective in high-risk spinal injury cases by inhibiting ectopic bone formation. Bisphosphonates are used off-label in fibrous dysplasia to alleviate and slow the progression of skeletal deformities, though evidence from randomized trials indicates variable radiographic improvements and primarily symptomatic benefits. Limited evidence supports the use of bisphosphonates for bone involvement in , and they are not recommended for owing to their inefficacy in addressing the underlying pathophysiology.

Safety and Adverse Effects

Common Side Effects

Bisphosphonates, particularly oral formulations such as alendronate and risedronate, commonly cause gastrointestinal adverse effects, including , dyspepsia, and , with incidence rates ranging from 8% to 28% in clinical practice. These effects arise due to poor absorption in the upper and are more frequent with oral than intravenous forms, often leading to treatment discontinuation. Hypocalcemia occurs in up to 18% of patients, particularly with intravenous bisphosphonates, and is more common in those with or low calcium intake; monitoring and supplementation are recommended to prevent symptoms like or . Intravenous bisphosphonates, such as , frequently induce flu-like symptoms known as an acute phase reaction, characterized by fever, , , and fatigue, affecting approximately 30% to 42% of patients after the first dose. These symptoms typically onset within 24 to 48 hours, resolve within 2 to 3 days, and occur less often (less than 7%) with subsequent infusions. Musculoskeletal side effects, including transient bone, joint, or muscle pain, are reported in about 3% to 5% of users across both oral and intravenous bisphosphonates. These pains are usually mild and self-limiting but can emerge shortly after initiation or persist briefly. Intravenous administration may lead to mild, transient elevations in serum creatinine in a notable proportion of patients, though severe renal impairment is uncommon with proper dosing; oral forms rarely affect renal function. To minimize gastrointestinal side effects with oral bisphosphonates, patients should take the medication with a full glass of at least 30 minutes before the first or drink of the day and remain upright for at least 30 minutes, reducing incidence to under 5% when followed correctly.

Serious Risks

Bisphosphonates, particularly when used long-term, have been associated with (ONJ), a rare but debilitating condition characterized by exposed necrotic in the maxillofacial that fails to heal over eight weeks in the absence of . The incidence of ONJ is estimated at approximately 1 to 50 cases per 100,000 patient-years among patients treated for with oral bisphosphonates, but it rises significantly to 1% to 10% in patients receiving high-dose intravenous formulations such as or pamidronate. Risk factors include invasive dental procedures like tooth extractions, poor , , and uncontrolled , which can exacerbate local and . The underlying mechanism involves bisphosphonate-induced suppression of turnover, leading to impaired remodeling and increased susceptibility to oral microbial invasion in the jawbone, which has high remodeling activity. Preventive strategies, such as comprehensive dental evaluation before initiating therapy and maintaining good , are recommended to minimize this risk. Another serious long-term risk is atypical femoral fractures (AFFs), which are subtrochanteric or diaphyseal s with unique radiographic features, including minimal or no trauma, transverse or short oblique orientation, lateral cortical thickening, periosteal reaction, and—for incomplete fractures—a transverse radiolucent line in the lateral cortex known as the "dreaded black line." These fractures are primarily associated with prolonged (3-5+ years) anti-resorptive therapy such as bisphosphonates or denosumab for osteoporosis, though approximately 31% occur without bisphosphonate exposure. The risk increases with duration of therapy (e.g., adjusted hazard ratio of 7.29 after 5-7 years of bisphosphonate use compared to less than 1 year), but remains rare (5-year number needed to harm approximately 1424, compared to number needed to treat approximately 56 to prevent one hip fracture). Similar atypical fractures have been reported at non-femoral sites (e.g., ulna, tibia) in association with prolonged anti-resorptive therapy. Risk factors include Asian ethnicity, femoral geometry abnormalities like bowing, and concurrent use. Oversuppression of by bisphosphonates is thought to contribute, resulting in accumulated microdamage and reduced repair capacity; patients often experience prodromal symptoms such as or pain months before . The risk declines rapidly upon discontinuation, supporting monitoring for symptoms in long-term users. Upon diagnosis of AFF, management includes stopping anti-resorptive therapy, optimizing vitamin D and calcium status, protected weight-bearing for incomplete fractures, intramedullary nailing for complete fractures (with delayed healing expected), and consideration of anabolic agents such as teriparatide to prevent further fractures (though effects on healing are unclear). Concerns about atrial fibrillation (AF) emerged from early clinical trials, where bisphosphonate exposure showed a potential signal of increased serious AF events (odds ratio 1.47 in a meta-analysis of four datasets), with absolute risks around 1.3% in treated groups versus 0.5% in placebo. However, subsequent meta-analyses of observational studies and randomized controlled trials have not confirmed a causal link, reporting no significant association (odds ratio 1.10, 95% CI 0.95–1.28) and similar absolute incidences (1.4% versus 1.5% in controls over 25–36 months). This debated risk does not appear to alter routine cardiovascular monitoring recommendations for most patients. A weak association between oral bisphosphonates and has been noted in some observational studies, potentially linked to esophageal from improper administration. Nonetheless, multiple meta-analyses of cohort and case-control data have found no substantiated increased risk, with relative risks near 1.0 across studies evaluating durations of use exceeding three years. To mitigate these rare but serious risks, clinical guidelines as of 2024, including those from the National Guideline Group (NOGG), recommend considering drug holidays after 3 to 5 years of bisphosphonate therapy in patients at low-to-moderate fracture risk, with reassessment of and fracture risk at 2- to 4-year intervals to guide resumption or continuation; recent studies suggest extending holidays beyond 2 years may increase fracture risk. Recent updates emphasize screening for AFF risk factors and symptoms during long-term use, aligning with FDA communications on atypical fractures since 2010.

History and Development

Discovery

The conceptual origins of bisphosphonates trace back to the 19th-century synthesis of phosphonates, compounds featuring a carbon-phosphorus bond that were initially explored for industrial applications such as and inhibition. In the , research identified inorganic as a natural inhibitor of mineralization and soft-tissue , prompting investigations into stable synthetic analogues capable of mimicking this effect without rapid enzymatic degradation. The key discovery occurred in when Herbert Fleisch and colleagues demonstrated that methylenebisphosphonates, structurally analogous to with a central linking two moieties, potently inhibited ectopic in animal models such as rats and rabbits. This finding, detailed in full publications the following year, highlighted their potential to bind crystals and prevent pathological mineral deposition in soft tissues, marking the shift from industrial compounds to pharmacological agents. Early studies in the 1970s built on these observations by demonstrating bisphosphonates' inhibitory effects on osteoclasts , showing reduced in tissue cultures through direct interference with cellular activity rather than solely physicochemical mechanisms. The first non-nitrogenous bisphosphonate, etidronate (EHDP), was tested in clinical settings during this period for heterotopic ossification following , where it effectively prevented progressive bone formation in ectopic sites. Bisphosphonates were primarily developed by pharmaceutical companies and , with initial research emphasizing their anti-calcification properties over anti-resorptive applications in bone diseases.

Clinical Milestones

The first bisphosphonate to receive regulatory approval was etidronate, granted in 1977 in Europe and the for the treatment of . However, its clinical utility was constrained by a dose-dependent inhibition of bone mineralization, leading to osteomalacia-like defects at higher doses, which limited its long-term use. During the and , the development shifted toward more potent nitrogen-containing bisphosphonates, enhancing antiresorptive efficacy through mechanisms like inhibition of farnesyl pyrophosphate synthase. Pamidronate, an early nitrogenous agent, was approved by the FDA in 1991 for hypercalcemia of malignancy, marking a key advancement in applications. Alendronate followed in 1995 with FDA approval for postmenopausal , supported by pivotal trials such as the Fracture Intervention Trial (FIT), which demonstrated significant reductions in vertebral and hip fractures. In the 2000s, emerged as a highly potent third-generation bisphosphonate, approved by the FDA in 2001 for oncologic indications including hypercalcemia and bone metastases, and in 2007 for treatment based on the HORIZON-PFT trial showing superior fracture risk reduction with annual infusions. These extended dosing intervals, such as yearly intravenous administration, improved patient adherence compared to daily oral regimens. Meta-analyses in the , including a 2010 of antiresorptive , confirmed bisphosphonates' role in reducing vertebral risk by approximately 45-70%, though a suggested 10% reduction in overall mortality has not been confirmed by more recent meta-analyses (2019 and 2025). Recent 2024 studies have explored transitions from bisphosphonates to , showing sustained density gains and reduced risk with sequential , though rebound effects require careful monitoring, with 2025 research emphasizing strategies like bisphosphonate follow-up to mitigate risks post-denosumab. Ongoing research investigates synergies between bisphosphonates and inhibitors like , with preclinical and clinical data suggesting enhanced antiresorptive effects, though evidence for delays in coronary artery calcification progression remains inconclusive. No new bisphosphonate classes have been introduced since the .

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK470248/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6533426/
  3. https://www.mayoclinic.org/diseases-conditions/osteoporosis/in-depth/osteoporosis-treatment/art-20046869
  4. https://pubmed.ncbi.nlm.nih.gov/10423031/
  5. https://www.clinpgx.org/pathway/PA154423660
  6. https://aacrjournals.org/cancerres/article/65/12/4971/518128/Bisphosphonates-and-Cancer-Induced-Bone-Disease
  7. https://www.researchgate.net/figure/Structure-of-bisphosphonates-phosphate-carbon-phosphate-P-C-P-backbone-hydroxyl-OH_fig2_47756174
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC11023620/
  9. https://www.mayoclinicproceedings.org/article/S0025-6196(11)62358-6/fulltext
  10. https://pubs.acs.org/doi/pdf/10.1021/jm7015733
  11. https://www.nature.com/articles/nchembio.421.pdf
  12. https://www.sciencedirect.com/science/article/abs/pii/S8756328210020399
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC10721586/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC2667901/
  15. https://biomedpharmajournal.org/vol16no1/bisphosphonates-from-pharmacology-to-treatment/
  16. https://go.drugbank.com/drugs/DB00710
  17. https://pubmed.ncbi.nlm.nih.gov/9286751/
  18. https://pubmed.ncbi.nlm.nih.gov/11160603/
  19. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC2781185/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC9341147/
  22. https://pubmed.ncbi.nlm.nih.gov/8298197/
  23. https://reference.medscape.com/drug/fosamax-binosto-alendronate-342810
  24. https://www.acpjournals.org/doi/10.7326/M22-1034
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC1936260/
  26. https://academic.oup.com/jcem/article/97/7/2272/2833999
  27. https://academic.oup.com/jcem/article/85/11/4118/2853207
  28. https://academic.oup.com/jcem/article/110/3/e899/7699402
  29. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60250-6/fulltext
  30. https://www.nejm.org/doi/full/10.1056/NEJM200008313430902
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC2769231/
  32. https://academic.oup.com/jnci/article/94/19/1458/2519926
  33. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60908-4/fulltext
  34. https://ascopubs.org/doi/10.1200/JCO.21.02647
  35. https://ascopubs.org/doi/abs/10.1200/JCO.2001.19.2.558
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4683803/
  37. https://ashpublications.org/blood/article/121/17/3325/31224/Optimal-use-of-bisphosphonates-in-patients-with
  38. https://pubmed.ncbi.nlm.nih.gov/12796698/
  39. https://www.nejm.org/doi/full/10.1056/NEJMoa044241
  40. https://academic.oup.com/jcem/article/99/12/4408/2833929
  41. https://www.nejm.org/doi/full/10.1056/NEJM199810013391402
  42. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s057lbl.pdf
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC3218076/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC4223439/
  45. https://ashpublications.org/blood/article/104/5/1253/18891/Gaucher-disease-alendronate-disodium-improves-bone
  46. https://academic.oup.com/jcem/article/99/10/3607/2836350
  47. https://www.ajmc.com/view/aug04-1859ps207-s215
  48. https://www.sciencedirect.com/science/article/pii/S2352187215300218
  49. https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-024-00464-8
  50. https://academic.oup.com/jcem/article/95/9/4380/2835442
  51. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021575s017lbl.pdf
  52. https://pubmed.ncbi.nlm.nih.gov/23907861/
  53. https://www.ncbi.nlm.nih.gov/books/NBK534771/
  54. https://pubmed.ncbi.nlm.nih.gov/39172879/
  55. https://pubmed.ncbi.nlm.nih.gov/38198798/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC11479699/
  57. https://pubmed.ncbi.nlm.nih.gov/19338379/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC2875664/
  59. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0122646
  60. https://pubmed.ncbi.nlm.nih.gov/23052941/
  61. https://www.nature.com/articles/s41416-020-01043-9
  62. https://link.springer.com/article/10.1007/s00198-012-2158-8
  63. https://www.bonehealthandosteoporosis.org/patients/treatment/medicationadherence/
  64. https://www.nogg.org.uk/sites/nogg/download/NOGG-Guideline-2024.pdf
  65. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-update-osteoporosis-drugs-bisphosphonates-and-atypical
  66. https://pubmed.ncbi.nlm.nih.gov/22026164/
  67. https://www.nature.com/articles/195911a0
  68. https://www.science.org/doi/10.1126/science.165.3899.1262
  69. https://pubmed.ncbi.nlm.nih.gov/11879557/
  70. https://academic.oup.com/edrv/article/19/1/80/2530799
  71. https://www.nature.com/articles/sc197625
  72. https://www.ismni.org/jmni/pdf/27/03FRANCIS.pdf
  73. https://pubmed.ncbi.nlm.nih.gov/31911206/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC8076070/
  75. https://docentes.fct.unl.pt/ana-faisca/files/ref11.pdf
  76. https://dig.pharmacy.uic.edu/faqs/2024-2/sep-2024-faqs/what-is-the-comparative-safety-of-iv-bisphosphonates-for-the-treatment-of-hypercalcemia-in-patients-with-renal-dysfunction/
  77. https://www.sciencedirect.com/science/article/abs/pii/S8756328220301915
  78. https://www.nytimes.com/1995/10/03/science/new-osteoporosis-drug-wins-fda-approval.html
  79. https://www.nejm.org/doi/full/10.1056/NEJMoa067312
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC3095556/
  81. https://academic.oup.com/jcem/article/95/3/1174/2596951
  82. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2747869
  83. https://journals.lww.com/clinorthop/fulltext/2025/01000/can_bisphosphonate_therapy_reduce_overall.18.aspx
  84. https://journals.lww.com/md-journal/fulltext/2024/11150/sequential_treatment_from_bisphosphonate_to.20.aspx
  85. https://academic.oup.com/jbmr/article/40/9/1017/8064740
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC11429268/
  87. https://www.sciencedirect.com/science/article/pii/S2212137424001143
Add your contribution
Related Hubs
User Avatar
No comments yet.